Alteogen Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
5,527
7,043
4,727
6,844
12,104
Cost of Goods Sold (COGS) incl. D&A
127
166
214
6,277
11,159
Gross Income
5,401
6,876
4,513
567
945
SG&A Expense
3,849
6,152
4,389
5,978
7,119
EBIT
1,511
724
124
5,411
6,173
Unusual Expense
-
23
-
60
1,537
Non Operating Income/Expense
18
124
280
314
182
Interest Expense
118
98
7
1
2
Pretax Income
1,527
770
1,047
4,456
7,372
Income Tax
6
161
162
869
77
Equity in Affiliates
84
-
-
-
-
Consolidated Net Income
1,606
931
1,208
3,587
7,449
Net Income
1,606
931
1,208
3,587
7,449
Net Income After Extraordinaries
1,606
931
1,208
3,587
7,449
Net Income Available to Common
1,606
931
1,208
3,587
7,449
EPS (Basic)
347.00
114.00
103.00
298.00
597.00
Basic Shares Outstanding
11
8
12
12
12
EPS (Diluted)
151.26
106.47
99.68
287.92
596.92
Diluted Shares Outstanding
11
9
12
12
12
EBITDA
1,637
891
338
5,059
5,750
Other Operating Expense
40
-
-
-
-
Non-Operating Interest Income
152
245
649
582
522

About Alteogen

View Profile
Address
62 Yuseong-daero 1628beon-gil
Daejeon DE 34054
Korea, Republic Of
Employees -
Website http://www.alteogen.com
Updated 09/14/2018
Alteogen, Inc. engages in the development, manufacture, and sale of biopharmaceuticals and anticancer drugs. Its products include technologies for anti-breast cancer drug and biosimilar, technology consulting, and other services. The company was founded on May 13, 2008 and is headquartered in Daejeon, South Korea.